



# A Review on Promising Natural Agents Effective on Hyperlipidemia

**Mahmoud Bahmani, PhD<sup>1</sup>, Mahmoud Mirhoseini<sup>2</sup>,  
Hedayatollah Shirzad, PhD<sup>2</sup>, Mehrnoosh Sedighi, PhD<sup>2</sup>,  
Nejmeh Shahinfard, MSc<sup>2</sup>, and Mahmoud Rafieian-Kopaei, PhD<sup>2</sup>**

## Abstract

Hyperlipidemia is a prevalent disease and a major component of the metabolic syndrome resulting from various factors. This disease increases morbidity and mortality when combined with other prevalent diseases such as diabetes mellitus, hypertension, and cardiovascular diseases. The side effects of the current lipid-lowering drugs have increased the tendency to move toward traditional and alternative treatments. Epidemiological observations indicate that using alternative treatments, consumption of medicinal plants, diet, and consumption of fruits have had satisfactory results on the effects of hyperlipidemia in many societies. It should be noted that in majority of societies, even developed countries, the tendency toward eating lipid-lowering medicinal plants has increased extensively. Using these plants especially when common remedies cannot control the disease is significant. Although consumption of medicinal plants by hyperlipidemic patients may show improvement in disease state, drug interaction and side effects may cause complications in disease control. Therefore, in this review, apart from introducing some of the reliable plants effective in inhibition and decrease of hyperlipidemia, the possibility of their intoxication and drug interaction is also presented.

## Keywords

hyperlipidemia, lipid, medicinal plants

Received October 22, 2014. Accepted for publication December 21, 2014.

Nowadays, cardiovascular complications are considered as the main factors of morbidity and mortality. Globally, the number of deaths from cardiovascular diseases has increased from 14.4 million in 1990 to 17.5 million in 2005, and it is estimated to be about 20 million in 2015.<sup>1</sup> Some circulating agents such as low-density lipoprotein free radicals, homocysteine, and nicotine are also considered as leading factors. Morbidity and mortality increase when combined with other prevalent diseases such as diabetes mellitus and hypertension.<sup>2</sup>

The formation of atherosclerotic plaque involves accumulation of low-density lipoprotein in intima, low-density lipoprotein oxidation, uptake of oxidized low-density lipoprotein by macrophage scavenger receptors, influence of macrophages on foam cells, and stabilization of plaque. In all steps of atherosclerosis, inflammatory cytokines are involved and make this process a chronic inflammatory disease.<sup>3</sup>

When the blockage of the coronary arteries reaches more than 75%, usually the symptoms of angina will gradually appear. Blood clot usually develops on the irregular surfaces of arteries, which then may become detached, thus blocking the downstream blood flow. Heart attacks and strokes are usually caused by such blood clots. Moreover, the atherosclerotic blood vessels are generally weak and can burst. The best treatment in diseases

such as atherosclerosis is prevention. Therefore, conventional medical approaches generally focus on lifestyle changes, such as reduction in the consumption of saturated fats, quitting smoking, and aerobic exercise. Drugs are also used to lower cholesterol levels or blood pressure; however, most of them possess considerable side effects.<sup>4</sup>

Using alternative treatments, especially medicinal plants and their complements, to treat different diseases such as hyperlipidemia,<sup>5-7</sup> diabetes,<sup>7,8</sup> and cardiovascular diseases<sup>9-12</sup> has increased over the recent decades in majority of countries worldwide. One of the important problems faced by doctors and also users of medicinal plants is lack of enough information in the field of drug safety and its effect on disease.<sup>13,14</sup>

<sup>1</sup> Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Islamic Republic of Iran

<sup>2</sup> Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Islamic Republic of Iran

## Corresponding Author:

Mahmoud Rafieian-Kopaei, PhD, Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Islamic Republic of Iran.  
Email: rafieian@yahoo.com

Fortunately, extensive studies have been done on the effectiveness of medicinal plants used in traditional medicine over the 30 past years and some of their efficiencies and deficiency have been recorded.<sup>15-18</sup>

This review was therefore aimed to introduce some promising medicinal plants effective in the prevention or treatment of hyperlipidemia, apart from presenting the possibility of their intoxication and drug interaction.

## Lipid-Lowering Medicinal Plants

Different remedies are used to treat hyperlipidemia in traditional medicine in which the role of medicinal plants is significant. Recent researches performed on medicinal plants and food supplements used in traditional medicine indicate that compounds present in them including food fibers, vitamins, flavonoids, sterols, and other antioxidant compounds can lower lipids, inhibit low-density lipoprotein oxidation, eliminate oxygen free radicals, and possibly improve this disease by having an effect on the immune system and improving metabolic disorders of the body.<sup>19-22</sup>

### *Cynara cardunculus* (Artichoke)

In the early 20th century, French scientists stated this plant as liver and bile stimulator. Leaves of artichoke are used as diuretic to stimulate kidneys and as bile stimulator to release the flow of bile from the liver. Italian scientists used to prescribe the cynarin compound (effective substance of artichoke) to stimulate the liver and gallbladder and to treat elevated cholesterol.<sup>23</sup> Use of artichoke leaves stimulates bile production and results in dyspeptic problems being treated. There are no valid evidences indicating that leaves of this plant treat dyspeptic problems directly.<sup>24</sup> A number of animal studies suggest that artichoke leaves inhibit cholesterol synthesis in liver cells and also protect the liver from damages caused by chemical toxins.<sup>25</sup> According to a study performed on 143 patients with high cholesterol, leaves of artichoke improved the level of cholesterol significantly.<sup>26</sup> In this randomized, double-blind, placebo controlled, multicenter trial, the initial total cholesterol of patients was equal to or more than 280 mg/dL. Patients received 1.8 mg/day artichoke dry extract (n = 172) or placebo (n = 171) for 6 weeks. Total cholesterol was decreased 18.5% in the drug group versus 8.6% decrease in the placebo group; low-density lipoprotein cholesterol by 23% versus 6%; and low-density lipoprotein to high-density lipoprotein ratios by 20% versus 7%. Compounds present in the leaf of artichoke like cynarin and luteolin may play a significant role in reducing the synthesis of cholesterol as well as its total level.<sup>26</sup>

**Dosage.** According to Germany's Commission E, 6 g of the dried herb or its equivalent (totally 3 times per day) is the optimal dose to treat *dyspepsia*. However, the optimal dose for hyperlipidemia is not mentioned.<sup>27</sup>

**Toxicity.** No side effect has been observed in using leaves of artichoke so far, but since investigations in this regard are not complete, pregnant or nursing women are recommended not to use it. Also, young children or people with severe liver or kidney disease and individuals with gallstones should use the leaves with caution. Individuals with allergies to artichoke or similar plants (*Asteraceae* family) such as arnica or chrysanthemums should avoid using artichoke or cynarin preparations.<sup>27</sup>

### *Medicago sativa* (Alfalfa)

In traditional medicine, *Medicago sativa* is used as a dietary supplement, antidiabetic, antihyperlipidemic, and anti-allergen. It is also used to treat menstrual disorders, gastrointestinal tract disorders, kidney and urinary tract problems, burns, and arteritis. This plant is used as a dietary supplement, thanks to it containing high amounts of  $\beta$ -carotene and vitamins, including B, C, E, and K. Researches have suggested that seeds of *Medicago sativa* have the ability to decrease the blood cholesterol level in laboratory animals. Using seeds of this plant in monkeys for 1 year not only suggested no side effects but also reduced the blood cholesterol level.<sup>28</sup>

In this study in which the effects of alfalfa on aortas from cynomolgus monkeys with diet-induced atherosclerosis were evaluated, alfalfa resulted in varied degrees of regression of lesions. The results also showed that mean hydroxyproline as well as total glycosaminoglycan concentration in aortas was correlated with the severity of the lesions ( $P < .05$ ). These observations suggest that connective tissue components are intimately involved in remodeling the aorta during regression of diet-induced atherosclerosis.<sup>28</sup>

Laboratory studies have reported the presence of plant estrogens in this plant that may be useful to treat menstrual disorders. This plant is also used to treat pollinosis but clinical studies have not determined the effectiveness of this plant in the treatment of this disease.<sup>28,29</sup>

**Dosage.** In traditional medicine, 1 to 2 spoons of the powder of leaves or plant seeds that are infused in boiled water for 10 to 20 minutes are used. Pill or capsule of the plant should be used according to the instruction of the manufacturer.<sup>29</sup>

**Restrictions.** Due to estrogenic effects existing in some compounds of this plant, pregnant and nursing women or children should not use this drug.<sup>29</sup>

**Drug Interaction.** Due to high amount of vitamin K in this plant, the effects of warfarin in individuals who use this plant may decrease if it is used along with warfarin.<sup>30</sup>

**Toxicity.** Powder of plant and seeds of *Medicago sativa* contain L-cavanin, a substance that may cause disorder in blood cells and lead to the splenomegaly.<sup>30</sup>

### *Trigonella foenum graecum* L (Fenugreek)

In traditional medicine, *Trigonella foenum graecum* L is prescribed to treat diseases like diabetes, high cholesterol, bronchitis, constipation, dyspepsia, and renal problems. Studies conducted on laboratory animals and clinical studies suggest that this plant decreases the level of blood sugar in diabetic patients and lowers blood cholesterol. This plant like other food products containing high fiber can be useful to treat constipation. Twenty-five individuals with type 2 diabetes mellitus, in 2 drug (1 g of the extract per day) and placebo groups, were compared in a 2-month period. The level of blood sugar decreased significantly in the drug group compared with the placebo group, and the level of triglyceride decreased and high-density lipoprotein level increased in this group.<sup>30,31</sup>

Other animal and human studies have also suggested that fenugreek ameliorates blood triglycerides, total cholesterol, and low-density lipoprotein. It also prevents low-density lipoprotein from oxidation, which is one of the major components of atherosclerosis induction. These effects have been attributed to the plant's sapogenins and phytoestrogens. Sapogenins have been shown to increase biliary cholesterol excretion, and phytoestrogens indirectly increase thyroid hormones.<sup>31</sup>

**Dosage.** The usual dosage is 5 to 30 g of the plant seed powder 3 times per day in the meal time.<sup>31</sup>

**Toxicity.** This plant has mild gastrointestinal tract stimulatory effect, if it is used in high dose. No toxic effect was observed in animal studies as a result of eating this plant. The extract obtained from seed of *Trigonella foenum graecum* L has created the stimulatory effect on uterus of guinea pig. For this reason, pregnant women are recommended to avoid eating this plant, and it should not be used by children and patients with renal and liver diseases.<sup>30</sup>

**Drug Interaction.** Seed of *Trigonella foenum graecum* L intensifies the effect of insulin or other blood sugar-lowering drugs due to blood sugar lowering property.<sup>30</sup>

### *Allium sativum* L

*Allium sativum* L (garlic) is used in the treatment of an extensive range of diseases. The aromatic compound alliin is one of the most important compounds that exist in *Allium sativum* L. When garlic is cut or pressed, an enzyme named Alinase affects alliin, transforming it to allicin, which is the main factor of the strong odor of the garlic.<sup>32</sup> Today, garlic is used to treat gastrointestinal tract disorders, asthma, diabetes, cardiovascular diseases, hypercholesterolemia, common cold, and high blood pressure.<sup>33</sup> Although it is stated that using this plant decreases cholesterol and blood pressure, there are contradictory scientific evidences in this regard. Although some studies performed over the 1980 to 1990 decades suggested that garlic can decrease the blood cholesterol level, some more recent studies have shown contrary results.<sup>4,33,34</sup>

In a clinical study, taking the garlic capsules for 12 weeks, the compound was able to decrease cholesterol and low-density lipoprotein significantly in 46 patients with high blood cholesterol.<sup>35</sup> In this clinical trial, following 12 weeks of garlic supplement (n = 22), the total cholesterol and low-density lipoprotein cholesterol levels significantly decreased, while these parameters were not statistically changed in the placebo group (n = 24). In this study, no significant difference was observed in triglycerides or in low-density lipoprotein/high-density lipoprotein ratio between groups. The authors concluded that enteric-coated garlic supplements, with 9.6 mg allicin-releasing value, has potential to ameliorate the lipid profile of patients with mild to moderate hypercholesterolemia when they are recommended to have low-fat diet. Taken with other evidence, the ability of garlic extract for reduction of hypercholesterolemia might be attributed to allicin bioavailability, that is, greater anticholesterolemic efficacy might be evident at a higher allicin level.<sup>35</sup>

**Effect of Garlic on Atherosclerosis and Aorta Elasticity.** Primary information has suggested that garlic may be effective in inhibiting atherosclerosis formation, which is an important factor of cardiovascular diseases. It has been reported that garlic decreases formation of the atherosclerosis plaque in laboratory animals.<sup>4</sup> In a clinical study performed on 152 individuals, using 900 mg of garlic powder daily for 4 years decreased formation of the atherosclerosis plaques significantly.<sup>36</sup> In other clinical study performed on 200 individuals, the positive effect of the garlic in decreasing the formation of atherosclerosis plaque was observed.<sup>37</sup> In this study, healthy adults (n = 101; age = 50 to 80 years, matched with the same number in the control group) were administered 300 mg/day of garlic powder for at least 2 years. Pulse wave velocity, elastic vascular resistance, and pressure were used to measure the elastic properties of the aorta. The heart rate, blood pressure, and lipid profile were similar in the 2 groups. The pulse wave velocity ( $P < .0001$ ) and elastic vascular resistance ( $P < 0.001$ ) were lower in the garlic group than in the control group. Pulse wave velocity showed significant positive correlation with systolic blood pressure and age. Analysis of covariance and multiple regression analyses demonstrated that age and systolic blood pressure were the most important determinants of pulse wave velocity and that the effect of garlic on pulse wave velocity was independent of confounding factors. The authors concluded that garlic intake would protect the effect of the elastic properties of the aorta related to aging in humans.<sup>37</sup>

**Dosage.** The usual consumed dose of garlic powder is 900 mg daily that contains 1.3% alliin, that is, about 12 mg alliin daily. The most suitable proposed dose that has been obtained over clinical studies is about 10 mg alliin, which produces approximately 4 to 5 mg allicin. Using 1 to 7 g of alliin-free garlic daily has properties of fresh garlic.<sup>36</sup>

**Toxicity.** Using 2000 mg/kg body weight for 6 months created no negative phenomenon in rats. The most common side effect of

garlic is its undesired odor. Other side effects are observed rarely. For example, a study was performed on 1997 individuals who used normal dose of odorless garlic for 16 weeks. Nausea was seen in 6% of them, vertigo in about 1.3% (may be due to blood pressure decrease), and allergy in 1.1%. Limited reports also have been stated about headache, vertigo, hyperhidrosis, and tympanites.<sup>32</sup>

### **Glycine max (Soybean)**

Soya as a food product rich in protein is used in Asia and as free-cholesterol meat in traditional food of American people. The American Food and Drug Administration has allowed producers of food products containing soybean to use the healthy heart label on their products. In traditional medicine, soybean has been used to decrease blood cholesterol and also as an anticancer and anti-osteoporosis drug.<sup>32</sup>

**The Therapeutic Consumption of Soybean.** Several studies have suggested that soybean can decrease low-density lipoprotein in the blood. In a study performed on 38 individuals with high blood cholesterol, soybean decreased blood cholesterol and improved the low-density lipoprotein/high-density lipoprotein ratio. In this meta-analysis study the effect of soy protein intake was evaluated on serum lipid profile of hyperlipidemic patients. In most of the evaluated trials, the intake of cholesterol, fat, saturated fat, and energy was nearly equal in the control and soy-containing diet groups. The average soy protein intake was 47 g/day. Consumption of soy protein was associated with average changes in serum lipid profile as follows: a decrease of 23.2 mg/dL or 9.3% in cholesterol, a decrease of 21.7 mg/dL or 12.9% in low-density lipoprotein cholesterol, a decrease of 13.3 mg/dL or 10.5% in triglycerides. The ingestion of soy protein was associated with a nonsignificant 2.4% increase in serum concentrations of high-density lipoprotein cholesterol. The author concluded that consumption of soy protein is beneficial in hypercholesterolemic patients. Thus, soy protein rather than animal protein was able to significantly decrease the serum concentrations of triglycerides, total cholesterol, low-density lipoprotein cholesterol.<sup>38</sup> Some observations indicate that isoflavones available in soybean have an important role in decreasing blood cholesterol but some studies refute this. Moreover, proteins available in soybean may have more an important role compared with these flavones.<sup>3</sup>

**Dosage.** The US Food and Drug Administration recommends 25 g of soybean protein to decrease blood cholesterol, although consuming higher dose is more effective. Observations suggest that replacing 20 g of soy protein with meat protein decreases blood cholesterol significantly. Some studies prescribe 40 g daily.<sup>32</sup>

**Drug Interaction.** Soy may decrease the effect of thyroid drugs. Moreover, several evidences show that soy isoflavones can inhibit the performance of the thyroid gland, although this state may be only significant in individuals with iodine deficiency.

Of course, some studies also reject the effect of soy and its isoflavones on thyroid hormones. Finally, individuals with thyroid problems are recommended to avoid high amounts of soy. Soy can decrease absorption of iron, calcium, and zinc. To compensate this state, materials containing these compounds should be used 2 hours after the consumption of soy.<sup>32</sup>

**Toxicity.** Although soy and its isoflavones can cause harmful effects in some conditions, animal studies have suggested that soy has no toxic effect.<sup>18</sup> Clinical studies suggest that soy decreases the level of the testosterone hormone in men. Moreover, some studies indicate the presence of estrogenic property in soy isoflavones. For this reason, use by pregnant women can lead to embryo damage.<sup>32</sup>

### ***Silybum marianum* L**

The main components of *Silybum marianum* L extract is known as silymarin. Silimaryne, consisting of 4 compounds including silymarin, is a herbal drug with hepatoprotective properties and contains different compounds like flavonoids with antioxidant, cellular membrane stabilizing, and blood glutathione increasing properties, and its positive effect in improving different diseases including hyperlipidemia have been reported in laboratory studies.<sup>39-41</sup> Results of the clinical researches indicate that silimaryne can be presented as a blood cholesterol reducer in patients with hypercholesterolemia. Using 420 mg of silimaryne once a day decreased cholesterol concentration in bile in 15 patients with high blood cholesterol compared with the control group, indicating that cholesterol synthesis decreases in the liver.<sup>42</sup> In a clinical study performed on 14 patients with hypercholesterolemia type 2, silimaryne at a dose of 420 mg decreased the total cholesterol level and increased the blood high-density lipoprotein level. In a clinical study, administration of silimaryne to diabetic patients with the hyperlipidemia decreased the total cholesterol, low-density lipoprotein, and triglyceride levels.<sup>42</sup>

### **Red Yeast Rice**

Red yeast rice is an important foodstuff in the daily diet of Chinese people. This is native to China and is the secondary product that results from the fermentation of a kind of cooked rice that red yeast rice has grown on it. This material is prescribed in traditional Chinese medicine as blood circulation and food digestion stimuli.<sup>43</sup> It has been reported that prescription of red yeast rice decreases blood cholesterol, and this effect is attributed to the statins available in this material. Statins are prescribed as blood cholesterol lowering drugs. Red yeast rice contains some active compounds including monacolin K, dehydromonacolin, and monacolin I-VI in addition to starch, protein, fiber, sterols, and fatty acids. Researchers have stated that one of the components of this yeast, monacolin K, inhibits production of cholesterol via stopping the activity of the HMG-CoA reductase enzyme, which has an important role in cholesterol synthesis. Statins are a class of hypocholesterolemic drugs

that reduce cholesterol levels by inhibition of HMG-CoA reductase in the liver. This enzyme is responsible for the production of more than 70% of total cholesterol in the body.<sup>44</sup>

Although the amount of monacolin K in red yeast rice is lower than lovastatin (2% in 5 mg vs 20–40 mg), it acts similarly. For this reason, researchers have proposed that red yeast rice contains other compounds like sterols that possibly have a role in decreasing cholesterol.<sup>44</sup> In addition to laboratory studies on animals, red yeast rice has been studied clinically in order to study its cholesterol-lowering effect. In a study, patients used daily 1.2 g of the concentrated extract of yeast (containing approximately 13.5 mg monacolin) for 2 months. In this study, significant decrease in the total serum cholesterol level was observed. Moreover, serum high-density lipoprotein level in these people increased and the low-density lipoprotein and triglyceride levels decreased.<sup>45</sup>

**Dosage.** A product called colistin obtained from this yeast has entered into the China market and its dosage is 1.2 to 2.4 g daily with divided doses for 8 to 12 weeks.<sup>43</sup>

**Restrictions.** People with liver disorders and pregnant women should not use red yeast rice. With regard to the similar effect of red yeast rice and statin drugs, they should be used together under the supervision of a physician.<sup>43</sup>

**Toxicity.** Usually, consumption of this material is tolerable and generally has no side effects, but some effects like heart burn and mild vertigo have been observed.<sup>45</sup>

### *Commiphora mukul* (Guggul, Gugulipid)

*Commiphora mukul* is an adhesive gum that is obtained from the Mukul myrrh tree. In the traditional medicine of India, this material is combined with other plants and is applied to treat skin problems, nervous system pains, obesity, diabetes, digestive problems, rheumatoid pains, mouth infection, and menstrual problems.<sup>46</sup> To study the effect of this material on blood cholesterol, a study on 61 individuals was performed for 24 weeks. After 12 weeks of diet control, half of the individuals received placebo and other half received Guggul at 100 mg daily dose. After 12 weeks, the total cholesterol level decreased 11.7%, low-density lipoprotein level 12.7%, triglyceride 12%, and cholesterol-high-density lipoprotein ratio 11.1% in individuals who used Guggul, which was significant compared with the placebo group.<sup>47</sup> Moreover, a double-blind study performed on 228 individuals indicated similarity of this material's effect with that of clofibrate.<sup>48</sup> This multicentric, double-blind, crossover study was completed in 125 patients with Guggul and in 108 patients with clofibrate. None of the patients in the Guggul group showed significant side effect except one patient who showed some gastrointestinal symptoms, but not severe enough to necessitate withdrawal of the drug. Two patients in the clofibrate group showed flu-like syndrome and opted out of the study. In this clinical trial, which was conducted at Bombay and Bangalore, India, patients

consumed *Commiphora mukul* in a dose of 500 mg 3 times per day for 12 weeks. The results showed a significant reduction in serum triglycerides (average 22.6%) and serum cholesterol (average 23.6%) in 70% to 80% of patients who consumed gugulipid. The average reduction in serum triglycerides and cholesterol was 16.8% and 11%, respectively, in patients who consumed with clofibrate. The lipid-lowering effect of both drugs became evident 3 to 4 weeks following the start of the drug. In this study, hypertriglyceridemic patients responded better to clofibrate; however, hypercholesterolemic patients responded better to gugulipid therapy. Clofibrate had no effect on high-density lipoprotein; however, high-density lipoprotein was increased in 60% of cases who consumed gugulipid. A significant reduction in low-density lipoprotein cholesterol was observed in the responders to both drugs.<sup>48</sup>

**Dosage.** Dosage depends on Guggul concentration and the level of the blood lipid, and usually 100 mg daily is prescribed.<sup>46</sup>

**Toxicity.** In clinical studies, no significant side effect has been reported after the administration of the standard extract of Guggul. Liver, renal, heart, and biochemical experiments indicate safe consumption of this material.<sup>46</sup>

## Dietary Plants Fibers With Hypolipidemic Activity

Dietary fibers are complex carbohydrate polymers with plant origin that are composed of simple sugars and generally are classified based on solubility.<sup>49</sup> Soluble fibers are made up of sticky substances like gum pectin and mucilage that are readily consumed by the bacteria in colon. Insoluble fibers consist of structural and/or matrix fibers such as lignin, cellulose, and hemicellulose, which are digested without change. Useful effects of dietary fibers in lowering blood lipids have been reported in clinical and laboratory researches.<sup>49</sup>

### *Plantago psyllium*

*Plantago psyllium* is water-soluble fiber derived from *Plantago ovate* seed husk. In a study conducted on individuals with hypercholesterolemia, 6 to 8 weeks of psyllium treatment decreased total cholesterol by 3.5% to 5.6% and low-density lipoprotein cholesterol by 5.1% to 8.8% compared with placebo treatment. In an experiment on 125 individuals with type 2 diabetes and hyperlipidemia, 5 g psyllium seed was taken 3 times per day for 6 weeks. In these patients, in addition to decrease in the blood glucose level, the total cholesterol, low-density lipoprotein cholesterol, and plasma triglyceride levels decreased after 2 weeks of treatment, while the high-density lipoprotein cholesterol level increased.<sup>50</sup>

In this study, the hydrophilic mucilloid of psyllium was examined in 75 hypercholesterolemic patients for its ability to lower serum cholesterol. Patients with mild to moderate hypercholesterolemia were included in this double-blind, randomized, placebo-controlled parallel trial. In step I, the patients

were treated with a diet for 12 weeks before receiving placebo or 3.4 g of psyllium 3 times/day for 8 weeks. Reported adherence to diet and treatment was high, and no significant adverse side effects were noted. In comparison to placebo, psyllium achieved an additional 4.8% reduction in total cholesterol level, 8.2% reduction in low-density lipoprotein cholesterol level, and 8.8% reduction in apolipoprotein B level, with no significant effect on blood pressure, serum glucose, or levels of triglycerides, high-density lipoprotein, or iron. The authors concluded that the hydrophilic mucilloid of psyllium was an effective and well-tolerated adjunct to diet in the management of mild to moderate hypercholesterolemia.<sup>51</sup>

**Use in Pregnancy and Breast-feeding.** No harmful side effects have been observed as a result of using the *Plantago ovate* seed or its seed husk, if the usual dose is used during pregnancy and breast feeding.<sup>51</sup>

**Drug Interaction.** Insulin-dependent diabetic patients may need to reduce the insulin dosage while using *plantago ovate* seed. The drug interaction between *plantago ovate* seed with lithium and carbamazepine has been reported. The simultaneous use of drug and *plantago ovate* seed may cause problems in drug intake. So it is recommended to use the seed of this plant ½ to 1 hour after the use of the drug. *Plantago ovate* seeds that are used mainly as emollient may cause subcutaneous emphysema. A large amount of water (not juice or other liquids) should be used to maintain the levels of water excreted. If there is no external water, *plantago ovate* seed absorb the water from wet mucous membrane of the gastrointestinal tract, which may lead to the damage of a part of bowel that is accompanied by intense abdominal pain.<sup>51</sup>

**Dose.** The dose is 5 to 15 g of the seed husk but administration of 5 g of the seed husk to decrease the glucose level and blood lipid has been stated in a report.<sup>52</sup>

### *Cyamopsis retragonoloba* (Guar Gum)

Guar gum is the nutrient derived from the edible seed of the *Cyamopsis retragonoloba* plant, which is an ingenuous plant of Asian countries. Laboratory studies showed that administration of guar gum to rat decreased the blood cholesterol level significantly in these animals. This effect was attributed to the effect of this dietary fiber on enterohepatic circulation. It has been stated that guar gum also decreases the fat intake available in foods by affecting the microflora of the gastrointestinal tract.<sup>53</sup> In addition, reports presented in other researches indicate that the lowering of blood cholesterol by guar gum is possibly due to the increase of steroids' excretion in feces and also increase of bile production.<sup>54</sup> It has been reported that administration of guar gum decreases appetite and in addition decreases cholesterol and triglyceride levels, and as a result weight of laboratory animals is decreased. In clinical studies also administration of guar gum to individuals with type 2

diabetes and hyperlipidemia decreased sugar and blood lipid levels.<sup>54</sup>

**Dose.** A dose of 15 g daily should be used to decrease cholesterol.<sup>27</sup>

### Oat

Oats as a foodstuff containing high fiber, in addition to different nutritional properties, can decrease the blood cholesterol level. In a study, 152 patients whose low-density lipoprotein levels was between 120 and 190 and triglyceride levels lower than 400 were fed oat diet for 6 weeks and the total cholesterol and low-density lipoprotein levels decreased.<sup>53</sup> A study showed that diet containing oat has a positive effect on body metabolism of women who are overweight. Using oat also led to decrease in the cholesterol level and low-density lipoprotein levels of individuals with hyperlipidemia in this study. Moreover, it has been stated that antioxidant properties of oat inhibit low-density lipoprotein oxidation, dose-dependently.<sup>54</sup>

**Dose.** Dose for individuals with hyperlipidemia has been reported to be 28 g/day.<sup>27</sup>

## Discussion

Hyperlipidemia has been shown to affect the antioxidant status of different organs as well as their lipoprotein levels.<sup>55-57</sup> Lipid-lowering medicinal plants may reduce hyperlipidemia, preventing atherosclerosis and vascular endothelium damage.<sup>58,59</sup> In most cases this effect and even the other effects of medicinal plants, at least in part, have been attributed to their antioxidant properties.<sup>60-63</sup>

Hyperlipidemia increases the production of free radicals, which in turn increases oxidative stress and low-density lipoprotein oxidation. During this process, low-density lipoprotein converts to oxidized low-density lipoprotein, induces the expression of adhesion molecules, stimulates activation of T cells and macrophages, increases the production of foam cells, and attracts macrophages to the sarcoplasmic reticulum. Oxidation of low-density lipoprotein has a crucial role in the formation of atherosclerotic plaques.<sup>64,65</sup>

Initially, lipophilic antioxidants preserve low-density lipoprotein particles against deformation, but in case of antioxidant deficiency unsaturated fatty acids will be oxidized. In this step of oxidation, low-density lipoprotein particles usually undergo slight changes. However, if this step continues and causes more accumulate of lipid oxidation products, these components start reacting with amino acids of ApoB-100 protein and cause covalent bond formation, resulting in increase in degradation of their protein part of low-density lipoprotein.<sup>66-68</sup>

Ox-low-density lipoprotein has a wide variety of effects such as chemokine expression, monocytes proliferation, chemotaxis of monocytes, fat cells formation, inhibition of macrophages movement, expression of endothelial adhesion molecules, growth factor stimulation,<sup>69</sup> fatty streaks formation,

and thickening of intima. All of these changes are effective in the progress of atherosclerosis.<sup>70-73</sup>

Inflammation is also related to coronary artery diseases. For example, C-reactive protein, which reflects extravascular inflammation, is increased in atherosclerosis and its complications.<sup>7</sup> It has been shown that patients with high C-reactive protein levels are also more prone to hypertension and diabetes mellitus, and both of these are related to atherosclerosis.<sup>74</sup> Reduction of free radicals by plants antioxidants, therefore, which scavenge free radicals and reduce oxidative stress, apart from reducing hyperlipidemia, can reduce the possibility of atherosclerosis.

Antioxidants such as beta-carotene, selenium, and vitamins C and E were considered as being able to prevent cell membrane oxidation.<sup>75,76</sup> However, recently their widespread use has been recommended to be limited because of their toxic effects or being ineffective. Therefore, natural compounds with antioxidant activity, which mostly have low toxic effects, seem to have beneficial effects.

In this regard, the Food and Nutrition Board decreased the recommended dietary allowance for some of these agents. Since the last report of the recommended dietary allowance, in 1989, the Food and Nutrition Board has changed the criteria for establishing recommended dietary allowances from prevention of deficiency diseases to prevention of chronic diseases. However, the revised recommended dietary allowances by the Panel on Dietary Antioxidants and Related Compounds of the Food and Nutrition Board were not based on the prevention of chronic diseases but based primarily on the prevention of deficiency symptoms. Hence, the new recommended dietary allowances for dietary antioxidants were different from the recommended dietary allowances published in 1989. The new recommended dietary allowances for adults are as follows: vitamin C, 75 mg/day for women and 90 mg/day for men; vitamin E, 15 mg/day or 22 IU for women and men; and selenium, 55 µg/day for women and men.<sup>77</sup>

The Panel considered the possibility that intakes higher than the recommended dietary allowances might prevent chronic diseases, but concluded that there were insufficient data to *prove* that increased intake of antioxidants exert beneficial health effects beyond the prevention of deficiency symptoms. The Panel established values for the upper intake level for dietary antioxidants too. The upper intake level is defined as “the highest level of daily nutrient intake that is likely to pose no risk of adverse health effects to almost all individuals in the general population.” The upper intake levels for adult men and women are the following: 2 g/day for vitamin C, 1000 mg/day for vitamin E, and 400 µg/day for selenium.<sup>77</sup>

Herbal medicine extracts mostly have antioxidant properties.<sup>78-81</sup> Therefore, as a source of different antioxidants, they can be very effective in modulating oxidative stress, thus protecting different organs such as heart,<sup>10</sup> kidney,<sup>82-86</sup> and liver,<sup>87-89</sup> from oxidative damages.<sup>90-92</sup>

Although different components of plants can have antioxidant effects, the main part of such effects is attributed to phenol compounds.<sup>93-95</sup> A lot of medicinal herbs such as *Ocimum*

*basilium*, *Allium sativum*, *Silybum marianum*, *Anethum graveolens*, *Boswellia carterii*, *Juglans regia*, *Trigonella foenum-graecum*, *Berberis vulgaris*, *Nigella sativa*, *Sesamum indicum*, *Aloe vera*, *Ziziphus jujube*, and *Zingiber officinale* possess antioxidant activities thanks to their phenolic compounds.<sup>18,66,96-102</sup> Some of these plants have been examined for their hypolipidemic activities and the others are worth examining.

## Conclusion

Today, hyperlipidemia and its resultant side effects have been known as one of the medicinal problems in most societies. Hyperlipidemia, in addition, intensifies metabolic disturbances and increases the risk of cardiovascular diseases, especially in patients with diabetes and blood pressure. Available information indicates that compounds available in food supplements and medicinal plants including dietary fibers, vitamins, flavonoids, sterols, and other antioxidants can be effective for the metabolism of lipids by influencing the metabolic reactions of different tissues. In most cases the lipid-lowering properties of these plants, at least in part, have been attributed to their antioxidant properties, and a lot of medicinal plants possess antioxidant properties.<sup>103-106</sup> Therefore, it might be useful to examine other medicinal plants that have antioxidant activities for their hypolipidemic activities.

## Acknowledgement

This article has been prepared with support from the Research Deputy of Shahrekord University of Medical Sciences.

## Author Contributions

All the authors wrote the first draft of the article together. MRK revised and edited the last version.

## Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

## Ethical Approval

This study is exempt from oversight by human subjects research protection as there were no human subjects involved.

## References

1. World Health Organization. *The Global Burden of Disease: 2004 Update*. Geneva, Switzerland: World Health Organization; 2008.
2. Eisenberg DM, David RB, Ettner SL. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. *JAMA*. 1998;280:1569-1575.
3. Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: process, indicators, risk factors and new hopes. *Int J Prev Med*. 2014;5:927-946.

4. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. *JAMA*. 1984;251:351-364.
5. Nasri H, Sahinfard N, Rafieian M, Rafieian S, Shirzad M, Rafieian-Kopaei M. Effects of *Allium sativum* on liver enzymes and atherosclerotic risk factors. *J HerbMed Pharmacol*. 2013; 2(2):23-28.
6. Asgary S, Sahebkar A, Afshani MR, Keshvari M, Haghjooyjavanmard S, Rafieian-Kopaei M. Clinical evaluation of blood pressure lowering, endothelial function improving, hypolipidemic and anti-inflammatory effects of pomegranate juice in hypertensive subjects. *Phytother Res*. 2014;28:193-199. doi:10.1002/ptr.4977.
7. Gharipour M, Ramezani MA, Sadeghi M, et al. Sex based levels of C-reactive protein and white blood cell count in subjects with metabolic syndrome: Isfahan Healthy Heart Program. *J Res Med Sci*. 2013;18:467-472.
8. Bahmani M, Zargarani A, Rafieian-Kopaei M, Saki K. Ethnobotanical study of medicinal plants used in the management of diabetes mellitus in the Urmia, Northwest Iran. *Asian Pac J Trop Med*. 2014;7(suppl 1):348-354.
9. Bahmani M, Shirzad HA, Majlesi M, Shahinfard N, Rafieian-Kopaei M. A review study on analgesic applications of Iranian medicinal plants. *Asian Pac J Trop Med*. 2014;7(suppl 1):43-53.
10. Khosravi-Boroujeni H, Mohammadifard N, Sarrafzadegan N, et al. Potato consumption and cardiovascular disease risk factors among Iranian population. *Int J Food Sci Nutr*. 2012;63:913-920.
11. Sadeghi M, Khosravi-Boroujeni H, Sarrafzadegan N, et al. Cheese consumption in relation to cardiovascular risk factors among Iranian adults—IHHP study. *Nutr Res Pract*. 2014;8: 336-341.
12. Khosravi-Boroujeni H, Sarrafzadegan N, Mohammadifard N, et al. White rice consumption and CVD risk factors among Iranian population. *J Health Popul Nutr*. 2013;31:252-261.
13. Rafieian-Kopaei M. Medicinal plants and the human needs. *J HerbMed Pharmacol*. 2012;1(1):1-2.
14. Nasri H, Shirzad H. Toxicity and safety of medicinal plants. *J HerbMed Pharmacol*. 2013;2(2):21-22.
15. Bahmani M, Rafieian-Kopaei M. Medicinal plants and secondary metabolites for leech control. *Asian Pac J Trop Dis*. 2014;4: 315-316.
16. Delfan B, Bahmani M, Hassanzadazar H, Saki K, Rafieian-Kopaei M. Identification of medicinal plants affecting on headaches and migraines in Lorestan Province, West of Iran. *Asian Pac J Trop Med*. 2014;7(suppl 1):376-379.
17. Amirmohammadi M, Khajoenia S, Bahmani M, Rafieian-Kopaei M, Eftekhari Z, Qorbani M. In vivo evaluation of antiparasitic effects of *Artemisia abrotanum* and *Salvia officinalis* extracts on *Syphacia obvelata*, *Aspiculuris tetrapetra* and *Hymenolepis nana* parasites. *Asian Pac J Trop Dis*. 2014;4(suppl 1):250-254.
18. Bahmani M, Saki K, Rafieian-Kopaei M, Karamati SA, Eftekhari Z, Jelodari M. The most common herbal medicines affecting *Sarcocystis* branches: a review study. *Asian Pac J Trop Med*. 2014;7(suppl 1):14-21.
19. Asgary S, Kelishadi R, Rafieian-Kopaei M, Najafi S, Najafi M, Sahebkar A. Investigation of the lipid-modifying and anti-inflammatory effects of *Cornus mas* L. supplementation on dyslipidemic children and adolescents. *Pediatr Cardiol*. 2013; 34:1729-1735.
20. Madihi Y, Merrikhi A, Baradaran A, et al. Bioactive components and the effect of hydroalcoholic extract of *Vaccinium myrtillus* on postprandial atherosclerosis risk factors in rabbits. *Pak J Med Sci*. 2013;29(1 suppl):384-389.
21. Asgary S, Rafieian-Kopaei M, Shamsi F, Najafi S, Sahebkar A. Biochemical and histopathological study of the anti-hyperglycemic and anti-hyperlipidemic effects of cornelian cherry (*Cornus mas* L.) in alloxan-induced diabetic rats. *J Complement Integr Med*. 2014;11(2):63-69.
22. Madihi Y, Merrikhi A, Baradaran A, et al. Impact of sumac on postprandial high-fat oxidative stress. *Pak J Med Sci*. 2013;29: 340-345.
23. Brand N. *Cynara scolymus* L.—the artichoke. *Z Phytother*. 1990; 11:169-175.
24. Kupke D, von Sanden H, Trinczek-Gartner H. An evaluation of the choleretic activity of a plant-based cholagogue. *Z Allgemeinmed*. 1991;67:1046-1058.
25. Heidarian E, Rafieian-Kopaei M. Protective effect of artichoke (*Cynara scolymus*) leaf extract against lead toxicity in rat. *Pharm Biol*. 2013;51:1104-1109.
26. Englisch W, Beckers C, Unkauf M, Ruepp M, Zinserling V. Efficacy of artichoke dry extract in patients with hyperlipoproteinemia. *Arzneimittelforschung*. 2000;50:260-265.
27. Blumenthal M. *The Complete German Commission E Monographs, Therapeutic Guide to Herbal Medicines*. Boston, MA: American Botanical Council; 1998:84.
28. Radhakrishnamurthy B, Ruiz HA, Dalferes ER, Srinivasan SR, Foster TA, Berenson GS. Studies of arterial wall glycosaminoglycans and collagen during experimental regression of atherosclerotic lesions in cynomolgus monkeys. *Lab Invest*. 1982;47: 153-159.
29. Colodny LR, Montgomery A, Houston M. The role of esterified alfalfa saponins in reducing cholesterol. *Am Nutraceutical Assoc*. 2001;3:6-15.
30. Miller LG. Herbal medicinals. Selected clinical considerations focusing on known or potential drug-herb interactions. *Arch Intern Med*. 1998;158:2220-2211.
31. Basch E, Ulbricht C, Kuo G, Szapary Ph, Smith M. Therapeutic applications of fenugreek. *Altern Med Rev*. 2003;8:20-27.
32. Schulz V, Hansel R, Tyler VE. *Rational Phytotherapy: A Physicians' Guide to Herbal Medicine*. 3rd ed. Berlin, Germany: Springer-Verlag; 1998:112.
33. Shirzad H, Taji F, Rafieian-Kopaei M. Correlation between antioxidant activity of garlic extracts and WEHI-164 fibrosarcoma tumor growth in BALB/c mice. *J Med Food*. 2011;14: 969-974.
34. Nasri H, Nematbakhsh M, Rafieian-Kopaei M. Ethanol extract of garlic for attenuation of gentamicin-induced nephrotoxicity in Wistar rats. *Iran J Kidney Dis*. 2013;7:376-382.
35. Kannar D, Wattanapenpaiboon N, Savige GS. Hypocholesterolemic effect of an enteric-coated garlic supplement. *J Am Coll Nutr*. 2001;20:225-231.
36. Koscielny J, Klussendorf D, Latza R. The antiatherosclerotic effect of *Allium sativum*. *Atherosclerosis*. 1999;144:237-249.



37. Breithaupt-Grogler K, Ling M, Boudoulas H. Protective effect of chronic garlic intake on elastic properties of aorta in the elderly. *Circulation*. 1997;96:2649-2655.
38. Anderson JW, Johnstone BM, Cooke-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. *N Engl J Med*. 1995;333:276-281.
39. Svagera Z, Skottova N, Vana P, et al. Plasma lipoproteins in transport of silibinin, an antioxidant flavonolignan from *Silybum marianum*. *Phytother Res*. 2003;17:524-530.
40. Kabiri N, Ahangar-Darabi M, Setorki M, Rafieian-kopaei M. The effect of silymarin on liver injury induced by thioacetamide in rats. *J HerbMed Pharmacol*. 2013;2(2):29-33.
41. Heidarian E, Rafieian-Kopaei M. Effect of silymarin on liver phosphatidate phosphohydrolase in hyperlipidemic rats. *Biosci Res*. 2012;9(2):59-67.
42. Nassuato G, Iemmolo RM, Strazzabosco M, et al. Effect of silibinin on biliary lipid composition experimental and clinical study. *J Hepatol*. 1991;12:290-295.
43. Burnham TH, Sjweain SL, Short RM, eds. *Monascus*. In: *The Review of Natural Products*. St Louis, MO: Facts and Comparisons; 1997.
44. Li C, Zhu Y, Wang Y. *Monascus purpureus*-fermented rice (red yeast rice): a natural food product that lowers blood cholesterol in animal models of hypercholesterolemia. *Nutr Res*. 1998;18:71-81.
45. Wang J, Lu Z, Chi J. Multicenter clinical trial of the serum lipid-lowering effects of a *Monascus purpureus* (red yeast) rice preparation from traditional Chinese medicine. *Curr Ther Res*. 1997;58:964-977.
46. Satyavati GV. Gum guggul (*Commiphora mukul*) the success story of an ancient insight leading to a modern discovery. *Indian J Med Res*. 1988;87:327-335.
47. Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of *Commiphora mukul* as an adjunct to dietary therapy in patients with hypercholesterolemia. *Cardiovasc Drugs Ther*. 1994;8:659-664.
48. Nityanand S, Srivastava JS, Asthana OP. Clinical trials with guggulipid. A new hypolipidaemic agent. *J Assoc Physicians India*. 1989;37:323-328.
49. Gray DS. The clinical uses of dietary fiber. *Am Fam Physician*. 1995;51:419-426.
50. Bell LP, Hectorne K, Reynolds H, Balm TK, Hunninghake DB. Cholesterol-lowering effects of psyllium hydrophilic mucilloid. *JAMA*. 1989;261:3419-3423.
51. Libster M. *Herb Guide for Nurses*. Boston, MA: Delmar, Thomson Learning; 2002:450-457.
52. Rodriguez-Moran M, Guerrero-Romero F, Lazcano-Burciaga G. Lipid- and glucose-lowering efficacy of *Plantago psyllium* in type II diabetes. *J Diabetes Complications*. 1998;12:273-278.
53. Seal CJ, Mathers JC. Comparative gastrointestinal and plasma cholesterol responses of rats fed on cholesterol-free diets supplemented with guar gum and sodium alginate. *Br J Nutr*. 2001;85:317-324.
54. Maisonnier S, Gomez J, Bree A, Berri C, Baeza E, Carre B. Effects of microflora status, dietary bile salts and guar gum on lipid digestibility, intestinal bile salts, and histomorphology in broiler chickens. *Poult Sci*. 2003;82:805-814.
55. Karmally W, Montez MG, Palmas W, et al. Cholesterol-lowering benefits of oat-containing cereal in Hispanic Americans. *J Am Diet Assoc*. 2005;105:967-970.
56. Setorki M, Nazari B, Asgary S, Azadbakht L, Rafieian-Kopaei M. Antiatherosclerotic effects of verjuice on hypocholesterolemic rabbits. *Afr J Pharm Pharmacol*. 2011;5:1038-1045.
57. Sarrafzadegan N, Khosravi-Boroujeni H, Esmailzadeh A, Sadeghi M, Rafieian-Kopaei M, Asgary S. The association between hypertriglyceridemic waist phenotype, menopause, and cardiovascular risk factors. *Arch Iran Med*. 2013;16:161-166.
58. Asadi-Samani M, Bahmani M, Rafieian-Kopaei M. The chemical composition, botanical characteristic and biological activities of *Borago officinalis*: a review. *Asian Pac J Trop Med*. 2014;7(suppl 1):22-28.
59. Bahmani M, Rafieian-Kopaei M, Jeloudari M, et al. A review of the health effects and uses of drugs of plant licorice (*Glycyrrhiza glabra* L.) in Iran. *Asian Pac J Trop Dis*. 2014;4(suppl 2):847-849.
60. Asadbeigi M, Mohammadi T, Rafieian-Kopaei M, Saki K, Bahmani M, Delfan B. Traditional effects of medicinal plants in the treatment of respiratory diseases and disorders: an ethnobotanical study in the Urmia. *Asian Pac J Trop Med*. 2014;7(suppl 1):S364-S368.
61. Baradaran A, Nasri H, Rafieian-Kopaei M. Oxidative stress and hypertension: possibility of hypertension therapy with antioxidants. *J Res Med Sci*. 2014;19:358-367.
62. Kafash-Farkhad N, Asadi-Samani M, Rafieian-Kopaei M. A review on phytochemistry and pharmacological effects of *Pran-gos ferulacea* (L.) Lindl. *Life Sci J*. 2013;10(8 suppl):360-367.
63. Bahmani M, Rafieian-Kopaei M, Hassanzadazar H, Saki K, Karamati SA, Delfan B. A review on most important herbal and synthetic antihelmintic drugs. *Asian Pac J Trop Med*. 2014;7(suppl 1):29-33.
64. Saki K, Bahmani M, Rafieian-Kopaei M. The effect of most important medicinal plants on two important psychiatric disorders (anxiety and depression)—a review. *Asian Pac J Trop Med*. 2014;7(suppl 1):34-42.
65. Nasri H, Rafieian-Kopaei M. Medicinal plants and antioxidants: why they are not always beneficial? *Iranian J Public Health*. 2014;43:255-257.
66. Nasri H, Rafieian-Kopaei M. Protective effects of herbal antioxidants on diabetic kidney disease. *J Res Med Sci*. 2014;19:82-83.
67. Baradaran A, Nasri H, Nematbakhsh M, Rafieian-Kopaei M. Antioxidant activity and preventive effect of aqueous leaf extract of aloe vera on gentamicin-induced nephrotoxicity in male Wistar rats. *Clin Ter*. 2014;165:7-11.
68. Rafieian-Kopaei M, Baradaran A, Rafieian M. Oxidative stress and the paradoxical effects of antioxidants. *J Res Med Sci*. 2013;18:629.
69. Shirzad H, Shahrani M, Rafieian-Kopaei M. Comparison of morphine and tramadol effects on phagocytic activity of mice peritoneal phagocytes in vivo. *Int Immunopharmacol*. 2009;9:968-970.
70. Rahimi-Madiseh M, Heidarian E, Rafieian-Kopaei M. Biochemical components of *Berberis lycium* fruit and its effects on lipid profile in diabetic rats. *J HerbMed Pharmacol*. 2014;3(1):15-19.
71. Rafieian-Kopaei M, Asgary S, Adelnia A, et al. The effects of cornelian cherry on atherosclerosis and atherogenic factors in hypercholesterolemic rabbits. *J Med Plants Res*. 2011;5:2670-2676.

72. Kazemi S, Asgary S, Moshtaghian J, Rafieian M, Adelnia A, Shamsi F. Liver-protective effects of hydroalcoholic extract of *Allium hirtifolium* Boiss in rats with alloxan-induced diabetes mellitus. *Arya Atherosclerosis*. 2010;6(1):11-15.
73. Asgary S, Rafieian-Kopaei M, Adelnia A, Kazemi S, Shamsi F. Comparing the effects of lovastatin and *Cornus mas* fruit on fibrogen level in hypercholesterolemic rabbits. *Arya Atherosclerosis*. 2010;6(1):1-5.
74. Bierman E. Atherosclerosis and other forms of atherosclerosis. In: Wilson H, Braunwald W, Martin G, Fauci G, Root S. *Harrison's Principles of Internal Medicine*. New York, NY: McGraw-Hill; 1991:992-996.
75. Nasri H, Rafieian-Kopaei M. Tubular kidney protection by antioxidants. *Iranian J Public Health*. 2013;42:1194-1196.
76. Rafieian-Kopaei M, Nasri H. Ginger and diabetic nephropathy. *J Renal Inj Prev*. 2012;2(1):9-10.
77. Linus Pauling Institute. The new recommendations for dietary antioxidants. <http://lpi.oregonstate.edu/s-s00/recommend.html>. Accessed December 5, 2014.
78. Karamati SA, Hassanzadazar H, Bahmani M, Rafieian-Kopaei M. Herbal and chemical drugs effective on malaria. *Asian Pac J Trop Dis*. 2014;4(suppl 2):599-601.
79. Asadi SY, Parsaei P, Karimi M, et al. Effect of green tea (*Camellia sinensis*) extract on healing process of surgical wounds in rat. *Int J Surg*. 2013;11:332-337.
80. Delfan B, Bahmani M, Rafieian-Kopaei M, Delfan M, Saki K. A review study on ethnobotanical study of medicinal plants used in relief of toothache in Lorestan Province, Iran. *Asian Pac J Trop Dis*. 2014;4(suppl 2):879-884.
81. Saki K, Bahmani M, Rafieian-Kopaei M, et al. The most common native medicinal plants used for psychiatric and neurological disorders in Urmia city, northwest of Iran. *Asian Pac J Trop Dis*. 2014;4(suppl 2):895-901.
82. Bahmani M, Rafieian M, Baradaran A, Rafieian S, Rafieian-Kopaei M. Nephrotoxicity and hepatotoxicity evaluation of *Crocus sativus* stigmas in neonates of nursing mice. *J Nephrothol*. 2014;3:81-85.
83. Baradaran A, Madihi Y, Merrikhi A, et al. Nephrotoxicity of hydroalcoholic extract of *Teucrium polium* in Wistar rats. *Pak J Med Sci*. 2013;29(1 suppl):329-333.
84. Rafieian-Kopaei M, Nasri H. The ameliorative effect of *Zingiber officinale* in diabetic nephropathy. *Iran Red Crescent Med J*. 2014;16:e11324.
85. Nasri H, Tavakoli M, Ahmadi A, Baradaran A, Nematbakhsh M, Rafieian-Kopaei M. Ameliorative effect of melatonin against contrast media induced renal tubular cell injury. *Pak J Med Sci*. 2014;30:261-265.
86. Ghaed F, Rafieian-Kopaei M, Nematbakhsh M, Baradaran A, Nasri H. Ameliorative effects of metformin on renal histologic and biochemical alterations of gentamicin-induced renal toxicity in Wistar rats. *J Res Med Sci*. 2012;17:621-625.
87. Taghikhani A, Afrough H, Ansari-Samani R, Shahinfard N, Rafieian-Kopaei M. Assessing the toxic effects of hydroalcoholic extract of *Stachys lavandulifolia* Vahl on rat's liver. *Bratisl Lek Listy*. 2014;115(3):121-124.
88. Namjoo A, Nasri H, Talebi-Juneghani A, Baradaran A, Rafieian-Kopaei M. Safety profile of *Carthamus tinctorius* L. in lactation: brain, renal and hepatotoxicity. *Pak J Med Sci*. 2013;29:378-383.
89. Taghikhani A, Ansarisamani R, Afrough H, et al. The hepatotoxic and nephrotoxic effects of *Stachys lavandulifolia* Vahl in rat. *J Mazandaran Univ Med Sci*. 2012;22(88):84-90.
90. Bagheri N, Rahimian Gh, Salimzadeh L, et al. Association of the virulence factors of *Helicobacter pylori* and gastric mucosal interleukin-17/23 mRNA expression in dyspeptic patients. *EXCLI J*. 2013;12:5-14.
91. Rahimian G, Sanei MH, Shirzad H, et al. Virulence factors of *Helicobacter pylori* vacA increase markedly gastric mucosal TGF- $\beta$ 1 mRNA expression in gastritis patients. *Microb Pathog*. 2014;67-68:1-7.
92. Bagheri N, Taghikhani A, Rahimian G, et al. Association between virulence factors of *Helicobacter pylori* and gastric mucosal interleukin-18 mRNA expression in dyspeptic patients. *Microb Pathog*. 2013;65:7-13.
93. Bahmani M, Karamati SA, Hassanzadazar H, et al. Ethnobotanical study of medicinal plants in Urmia city: identification and traditional using of antiparasites plants. *Asian Pac J Trop Dis*. 2014;4(suppl 2):906-910.
94. Delfan B, Bahmani M, Eftekhari Z, Jelodari M, Saki K, Mohammadi T. Effective herbs on the wound and skin disorders: a ethnobotanical study in Lorestan province, west of Iran. *Asian Pac J Trop Dis*. 2014;4(suppl 2):938-942.
95. Nasri H, Baradaran A, Ardalan MR, Mardani S, Momeni A, Rafieian-Kopaei M. Bright renoprotective properties of metformin: beyond blood glucose regulatory effects. *Iran J Kidney Dis*. 2013;7:423-428.
96. Rabiei Z, Rafieian-Kopaei M, Heidarian E, Saghaei E, Mokhtari S. Effects of *Zizyphus jujube* extract on memory and learning impairment induced by bilateral electric lesions of the nucleus Basalis of Meynert in rat. *Neurochem Res*. 2014;39:353-360.
97. Roohafza H, Sarrafzadegan N, Sadeghi M, Rafieian-Kopaei M, Sajjadi F, Khosravi-Boroujeni H. The association between stress levels and food consumption among Iranian population. *Arch Iran Med*. 2013;16:145-148.
98. Rafieian-Kopaei M, Gray AM, Spencer PS, Sewell RD. Contrasting actions of acute or chronic paroxetine and fluvoxamine on morphine withdrawal-induced place conditioning. *Eur J Pharmacol*. 1995;275:185-189.
99. Hosseini-asl K, Rafieian-Kopaei M. Can patients with active duodenal ulcer fast Ramadan? *Am J Gastroenterol*. 2002;97:2471-2472.
100. Parsaei P, Karimi M, Asadi SY, Rafieian-Kopaei M. Bioactive components and preventive effect of green tea (*Camellia sinensis*) extract on postlaparotomy intra-abdominal adhesion in rats. *Int J Surg*. 2013;11:811-815. doi:10.1016/j.ijsu.2013.08.014.
101. Sharafati R, Sharafati F, Rafieian-Kopaei M. Biological characterization of Iranian walnut (*Juglans regia*) leaves. *Turk J Biol*. 2011;35:635-639.
102. Rafieian-Kopaei M, Shahinfard N, Rouhi-Boroujeni H, Ghari-pour M, Darvishzadeh-Boroujeni P. Effects of *Ferulago angulata* extract on serum lipids and lipid peroxidation. *Evid Based Complement Alternat Med*. 2014;2014:680856. doi:10.1155/2014/680856.

103. Rahnama S, Rabiei Z, Alibabaei Z, Mokhtari S, Rafieian-Kopaei M, Deris F. Antiamnesic activity of Citrus aurantium flowers extract against scopolamine-induced memory impairments in rats. *Neurological Sciences*. 2014;1-8.
104. Rabiei Z, Rafieian-Kopaei M, Heidarian E, Saghaei E, Mokhtari S. Effects of zizyphus jujube extract on memory and learning impairment induced by bilateral electric lesions of the nucleus basalis of meynert in rat. *Neurochemical Research*. 2014;39(2):353-60.
105. Rabiei Z, Rafieian-Kopaei M. Neuroprotective effect of pretreatment with *Lavandula officinalis* ethanolic extract on blood brain barrier permeability in a rat stroke model. *Asian Pacific Journal of Tropical Medicine*. 2014;7:S421-S6.
106. Rabiei Z, Hojjati M, Rafieian-Kopaei M, Alibabaei Z. Effect of Cyperus rotundus tubers ethanolic extract on learning and memory in animal model of Alzheimer. *Biomedicine & Aging Pathology*. 2013;3(4):185-91.